Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Bastit

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Pirarubicin in advanced breast cancer: a French cooperative phase II studyM Spielmann, P Kerbrat, T Delozier, et al.
Bulletin Du Cancer|January 1, 1988
[Prognostic value of estrogen and progesterone receptors in the operable breast cancer: results of a uni- and multifactorial analysis]B Chevallier, F Heintzman, B Asselain, et al.
Cancer Treatment Reports|June 1, 1986
Phase II clinical evaluation of doxifluridineP Hurteloup, J P Armand, P Cappelaere, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Phase II trial of pirarubicin in epidermoid carcinoma of the head and neckP Cappelaere, N Guiochet, J Chauvergne, et al.
British Journal of Cancer|March 1, 1993
The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patientsB Chevallier, P Bastit, Y Graic, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancerJ Bonneterre, P Kerbrat, P Fargeot, et al.
Bulletin Du Cancer|January 1, 1989
[What are the prognostic factors in operable breast cancer without histologic axillary lymph node invasiveness. Results of an uni- and multifactorial analysis]B Chevallier, F Heintzman, V Mosseri, et al.
European Journal of Cancer & Clinical Oncology|March 1, 1989
Phase II trial of idarubicin (4-demethoxydaunorubicin) in advanced breast cancer. The Clinical Screening Group of the European Organization for Research and Treatment of CancerP Hurteloup, J P Armand, M Schneider, et al.
Cancer|December 15, 1988
Prognostic value of estrogen and progesterone receptors in operable breast cancer. Results of a univariate and multivariate analysisB Chevallier, F Heintzmann, V Mosseri, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase II trial of iproplatin in advanced squamous cell carcinoma of the head and neck, oesophagus and lungP Cappelaere, N Guiochet, P Bastit, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Pirarubicin in advanced breast cancer: a French cooperative phase II studyM Spielmann, P Kerbrat, T Delozier, et al.
Bulletin Du Cancer|January 1, 1988
[Prognostic value of estrogen and progesterone receptors in the operable breast cancer: results of a uni- and multifactorial analysis]B Chevallier, F Heintzman, B Asselain, et al.
Cancer Treatment Reports|June 1, 1986
Phase II clinical evaluation of doxifluridineP Hurteloup, J P Armand, P Cappelaere, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Phase II trial of pirarubicin in epidermoid carcinoma of the head and neckP Cappelaere, N Guiochet, J Chauvergne, et al.
British Journal of Cancer|March 1, 1993
The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patientsB Chevallier, P Bastit, Y Graic, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancerJ Bonneterre, P Kerbrat, P Fargeot, et al.
Bulletin Du Cancer|January 1, 1989
[What are the prognostic factors in operable breast cancer without histologic axillary lymph node invasiveness. Results of an uni- and multifactorial analysis]B Chevallier, F Heintzman, V Mosseri, et al.
European Journal of Cancer & Clinical Oncology|March 1, 1989
Phase II trial of idarubicin (4-demethoxydaunorubicin) in advanced breast cancer. The Clinical Screening Group of the European Organization for Research and Treatment of CancerP Hurteloup, J P Armand, M Schneider, et al.
Cancer|December 15, 1988
Prognostic value of estrogen and progesterone receptors in operable breast cancer. Results of a univariate and multivariate analysisB Chevallier, F Heintzmann, V Mosseri, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase II trial of iproplatin in advanced squamous cell carcinoma of the head and neck, oesophagus and lungP Cappelaere, N Guiochet, P Bastit, et al.
Pageof 5